The “Quantum computing for covalent inhibitors in drug discovery” project is led by Jonathan Hirst and Katie Inzani from the University of Nottingham and co-founder of Phasecraft, Ashley Montanaro.
One of the most promising applications of near-term quantum computers is accurately modelling systems where quantum mechanics plays a key role, such as in materials science, chemistry and even drug discovery.
The project will demonstrate how the combined power of quantum computing and classical simulation methods can tackle drug discovery for myotonic dystrophy.
Myotonic dystrophy is a genetic condition that causes progressive muscle weakness and wasting and often affects the electrical conduction system of the heart, breathing and swallowing muscles, bowels, lens of the eye and brain.
It is the most frequent muscular dystrophy worldwide, with an estimated 6,500 people affected in the UK and around 3.6 million people globally. As an inherited disease, myotonic dystrophy symptoms usually become more severe with each generation, with onset typically occurring after the age of 40. No treatments currently exist for the condition.
Bristol and London-based startup Phasecraft will apply its research in quantum algorithms to developing algorithms that can harness the developments made in quantum computing to help further drug discovery for the condition.
Phasecraft launched in 2019 as a spinout from UCL and the University of Bristol and is currently focused on developing quantum algorithms to the point of practical quantum advantage.
